The continuation grant from a reputable organization like the Bill & Melinda Gates Foundation is a positive development for AN2 Therapeutics. It not only provides financial support but also validates the potential of their research, which could lead to significant advancements in treatments for tuberculosis and malaria. This news is likely to boost investor confidence and positively impact the stock price in the short term.